CooperCompanies Cuts Guidance Amid Inventory Drags
CooperCompanies shares fell 13.9% after weak Q2 revenue and a decision to retain its surgical unit, prompting a reduction in full-year financial outlooks.
CooperCompanies (NASDAQ:COO) shares dropped 13.9% in afternoon trading on September 10, 2026, following the release of second-quarter results that missed revenue expectations. The medical device manufacturer reported $1.07 billion in sales, flat year-over-year, which fell short of the $1.10 billion analyst consensus. CEO Al White attributed the top-line stagnation to proactive inventory reductions in the U.S. channel at CooperVision, a trend he indicated will continue to weigh on performance in the coming quarter.
Despite the revenue miss, profitability metrics showed resilience, with operating margins expanding to 20.8% from 16.6% in the prior year. This margin improvement supported adjusted earnings of $1.15 per share, slightly exceeding the $1.12 consensus estimate. However, the market reaction was driven by operational headwinds and strategic decisions that altered the company’s near-term trajectory and valuation perception.
Management Lowers Full-Year Financial Outlook
Citing ongoing channel destocking pressures, management reduced its full-year revenue guidance midpoint from $4.30 billion to $4.24 billion. Concurrently, the company lowered its full-year adjusted earnings per share outlook to $4.53 at the midpoint. These adjustments reflect a more cautious view on near-term demand recovery, directly impacting the firm's projected cash flow and investment capacity for the remainder of fiscal 2026.
CooperSurgical Unit Retained After Strategic Review
CooperCompanies concluded a strategic review initiated in December 2025, with the board unanimously deciding to retain the CooperSurgical business. The board rejected acquisition proposals, citing valuation disconnects driven by incoming non-hormonal IUD competition and recent litigation settlements. To offset the retained operational burden, the company expanded its share repurchase authorization to $3 billion, signaling a commitment to shareholder returns despite the strategic pivot.
Market Reaction and Valuation Adjustments
The 13.9% decline marks one of the largest moves for CooperCompanies in the past year, a stock known for low volatility. The share price now stands at $54.81, representing a 32.4% drop since the start of the year and a 35% discount to its January 2026 high of $84.32. William Blair downgraded the stock to Market Perform, highlighting the unexpected decision to keep CooperSurgical and the persistent revenue pressure from inventory adjustments as key risks.
According to data reported by GN stocks/nasdaq, the sharp decline underscores a significant shift in market perception regarding the company’s growth engine. Investors who entered the position five years ago now see their $1,000 investment valued at approximately $485.77, reflecting the cumulative impact of recent operational challenges and strategic realignments on long-term shareholder returns.
